Castle Biosciences (CSTL) Other Operating Expenses (2020 - 2026)

Castle Biosciences has reported Other Operating Expenses for 7 years, with the latest figure at $26.0 million in Q2 2026.

• Quarterly Other Operating Expenses rose 32.49% year-over-year to $26.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $90.3 million (down 12.09% YoY) and the FY2025 annual result came in at $105.9 million, up 48.46% from the prior year.
• Other Operating Expenses rose to $26.0 million in Q2 2026 per CSTL's latest filing, from $22.8 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $44.7 million in Q1 2025 and troughed at -$10.6 million in Q2 2022.
• A 5-year average of $16.8 million and a median of $16.5 million in 2024 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2022 and 2026: Other Operating Expenses soared 235.34% in 2022, then tumbled 49.09% in 2026.
• Over 5 years, Other Operating Expenses stood at $11.4 million in 2022, then advanced by 28.5% to $14.7 million in 2023, then surged by 39.67% to $20.5 million in 2024, then gained by 0.33% to $20.6 million in 2025, then increased by 26.03% to $26.0 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $26.0 million, $22.8 million, and $20.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.